Stephen B. Howell

Moores Cancer Center

Medicine · Health Sciences

83h-index22.7kcitations536works0.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Drug Transport and Resistance Mechanisms(69), Trace Elements in Health(65), Chronic Myeloid Leukemia Treatments(65), Acute Myeloid Leukemia Research(57), Metal complexes synthesis and properties(52)

Publications536 total

Giant Outer Transiting Exoplanet Mass (GOTEM) Survey.VII. TOI-6041: a multi-planet system including a warm Neptune exhibiting strong TTVs
arXiv (Cornell University)·2025Open Access
Suppl Figure 8 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
2025Open Access
Suppl Figure 7 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
2025Open Access
Suppl Figure 2 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
2025Open Access
Supplementary Tables from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
2025Open Access
Suppl Figure 1 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
2025Open Access
Suppl Figure 4 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
2025Open Access
Suppl Figure 3 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
2025Open Access
Suppl Figure 6 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
2025Open Access
Suppl Figure 5 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
2025Open Access
Supplementary Data from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
2025Open Access
Suppl Figure 8 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
2025Open Access
Suppl Figure 4 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
2025Open Access
Supplementary Tables from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
2025Open Access
Suppl Figure 6 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
2025Open Access
Suppl Figure 3 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
2025Open Access
Suppl Figure 1 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
2025Open Access
Suppl Figure 7 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
2025Open Access
Suppl Figure 5 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
2025Open Access
Supplementary Data from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
2025Open Access
page 1 of 27Next →

Frequent Co-authors

Roohangiz Safaei(12), Alison K. Holzer(10), Goli Samimi(8), Kuniyuki Katano(7), Daniel Fink(6), Stefan Aebi(4), R D Christen(4), Paul A. Andrews(4), K. Thomas Robbins(4), Nissi Varki(4), Wiltrud Naerdemann(3), Marc C. Chamberlain(3), S Nebel(3), Myriam Rochdi(3), Christopher Larson(3), Michael J. Sailor(3), Xinjian Lin(3), Charles W. Kerber(3), Stephen L. Seagren(3), Barrett J. Larson(2)